Varenicline for Nicotine Vaping Cessation in Adolescents
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The study will test the hypothesis that varenicline, when added to group behavioral and
texting support for vaping cessation, will improve vaping abstinence rates in adolescents
dependent on vaped nicotine over placebo plus group behavioral and texting support for vaping
cessation. Approximately 225 adolescents will be randomly assigned to one of three arms (1)
varenicline up to 1 mg bid for 12 weeks plus behavioral and texting support for vaping
cessation (2) identical appearing placebo plus behavioral and texting support and (3)
monitoring only. The primary comparison will be the double-blind, placebo-controlled
comparison of vaping cessation rates in those assigned to varenicline vs placebo.